Louis Preston Garrison: Difference between revisions
Mbounthavong (talk | contribs) No edit summary |
Mbounthavong (talk | contribs) No edit summary |
||
| Line 59: | Line 59: | ||
==Awards and Recognition== |
==Awards and Recognition== |
||
In 2017, Garrison was selected as part of the PharmVOICE 100.{{cite web |url=http://www.pharmavoice.com/current-100/ |title=PharmaVOICE 100 — Class of 2017 |publisher=PharmVOICE |access-date=October 13, 2017}} Garrison was also honored by being inducted to New Albany High School Hall of Fame (2017),{{cite news |author=<!--Staff writer(s); no by-line.--> |title=New Albany High School Hall of Fame class announced |url=http://www.newsandtribune.com/news/new-albany-high-school-hall-of-fame-class-announced/article_86c754e2-59f1-11e7-ac0f-27906ccb99f3.html |work=News & Tribune |agency= |date= |
In 2017, Garrison was selected as part of the PharmVOICE 100.{{cite web |url=http://www.pharmavoice.com/current-100/ |title=PharmaVOICE 100 — Class of 2017 |publisher=PharmVOICE |access-date=October 13, 2017}} Garrison was also honored by being inducted to New Albany High School Hall of Fame (2017),{{cite news |author=<!--Staff writer(s); no by-line.--> |title=New Albany High School Hall of Fame class announced |url=http://www.newsandtribune.com/news/new-albany-high-school-hall-of-fame-class-announced/article_86c754e2-59f1-11e7-ac0f-27906ccb99f3.html |work=News & Tribune |agency= |date= June 25, 2017 |access-date = October 13, 2017 }} being honored for his life-time achievements at the [[Pharmaceutical Outcomes Research and Policy Program]] 20th Anniversary Research Symposium hosted by University of Washington School of Pharmacy (2016). |
||
==Legacy== |
==Legacy== |
||
Revision as of 03:53, 15 October 2017
 | This article, Louis Preston Garrison, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
Louis P. Garrison, Jr. | |
|---|---|
| Born | 1950 Indiana, USA |
| Citizenship | United States of America |
| Academic career | |
| Field | health economics |
| Institution | University of Washington |
| Alma mater | Stanford University (Ph.D.) Indiana University (B.S.) |
| Doctoral advisor | Victor Fuchs |
| Influences | Pharmacoeconomics |
| Website | sop |
Louis Preston Garrison, Jr. (born 1950) is an American health economist who has made significant contributions to pharmacoeconomics, pharmacogenomics and personalized medicine, regulatory benefit-risk analysis, insurance, pricing, reimbursement and risk-sharing agreements. He also made numerous contributions on the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, influenza, measles, obesity, and cancer. Garrison has published over a hundred manuscripts in peer-reviewed journals and contributed to several book chapters."ResearchGate". Retrieved October 13, 2017.
Education
Garrison received his B.A. in Economics at Indiana University and his Ph.D. in Economics at Stanford University. During his doctoral training, Garrison was mentored by Victor Fuchs, who was considered "the dean of health economists."[1]
Career
Garrison served as the president of the International Society for Pharmacoeconomics and Outcomes Research (2016-2017) and is Professor Emeritus at the University of Washington School of Pharmacy. Garrison’s career began with 13 years in non-profit health policy research at the Battelle Memorial Institute Human Affairs Research Centers (Seattle), and at the Project HOPE Center for Health Affairs (Virginia), where he was the Director from 1989-1992. Following this, he worked as an economist in the pharmaceutical industry for 12 years. From 2002-2004, he was Vice President and Head of Health Economics & Strategic Pricing in Hoffmann-La Roche Pharmaceuticals, and was based in Basel, Switzerland. He then joined the faculty at the University of Washington School of Pharmacy in 2004 until his retirement in 2017.
Incentives to Pharmaceutical Innovation
Garrison argued that a major challenge to pharmaceutical innovation has been the misalignment of incentives.[2] He further argued that the global product life cycle of oncology medications depended in large part to monopoly power associated with time-limited patent protection given by the Food and Drug Administration.
Value of Personalized Medicine
The advent of personalized medicine prompted discussion on its value and reimbursement decision. Garrison and MJ Finley Austin used a standard insure-payer reimbursement framework to identify that health systems reforms are necessary to develop economic incentives for personalized medicine.[3] Additionally, Garrison and Adrian Towse argue that value-based, flexible reimbursement for innovative, patent-protected diagnostic and therapeutic products needs to be value-based and flexible.[4] A global perspective is necessary to share the cost of innovative medicines, which will result in dynamic efficiency and global public goods. Personalized medicine is costly and requires society to share the costs through efficient pricing and reimbursement strategies.
Risk Sharing Agreements
Risk Sharing Agreements (RSA) are contracts between pharmaceutical companies and health care payers that link coverage reimbursement to pharmaceutical performance. Performance can be defined as financial-based and outcomes-based. Financial-based RSA has reimbursements tied to the market share and utilization of pharmaceutical. Whereas, outcomes-based RSA has reimbursements based on the drug's clinical/health outcomes. Garrison and colleagues reported that US health care payers expressed interest in financial-based RSA but were reluctant to implement outcomes-based RSA due to a lack of confidence.[5]
Awards and Recognition
In 2017, Garrison was selected as part of the PharmVOICE 100."PharmaVOICE 100 — Class of 2017". PharmVOICE. Retrieved October 13, 2017. Garrison was also honored by being inducted to New Albany High School Hall of Fame (2017),"New Albany High School Hall of Fame class announced". News & Tribune. June 25, 2017. Retrieved October 13, 2017. being honored for his life-time achievements at the Pharmaceutical Outcomes Research and Policy Program 20th Anniversary Research Symposium hosted by University of Washington School of Pharmacy (2016).
Legacy
Garrison and his wife established several several funds at the University of Washington: the Garrison Family Fund for Global Health Economics Education, the Louis Sr. and Marilyn Garrison Endowed Prize in Health Policy and Economics; and the Penny Evans Fund for the University of Washington International Society for Pharmacoeconomics and Outcomes Research Student Chapter.
References
- ^ Leonhardt, David (25 August 2009). "Real Choice? It's Off Limits in Health Bills". The New York Times.
- ^ Garrison, Louis P. (2010). "Rewarding Value Creation to Promote Innovation in Oncology:The Importance of Considering the Global Product Life Cycle". The Oncologist. 15 (suppl 1): 49–57. doi:10.1634/theoncologist.2010-S1-49.
- ^ Garrison, Louis P.; Austin, MJ Finley (2007). "The Economics of Personalized Medicine: A Model of Incentives for Value Creation and Capture". Therapeutic Innovation & Regulatory Science. 41 (4): 501–509. doi:10.1177/009286150704100408.
{{cite journal}}: Cite has empty unknown parameter:|1=(help) - ^ Garrison, Louis P.; Towse, Adrian (2017). "Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics". Journal of Personalized Medicine. 7 (10): 1–10. doi:10.3390/jpm7030010.
{{cite journal}}: Cite has empty unknown parameter:|1=(help)CS1 maint: unflagged free DOI (link) - ^ Garrison, Louis P.; Carlson, Josh; Bajaj, Preeti; Towse, Adrian; Neumann, Peter; Sullivan, Sean; Westrich, Kimberly; Dubois, Robert. "Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects". The American Journal of Managed Care. 21 (21): 632–640. PMID 26618366.
Template:Presidents of the International Society for Pharmacoeconomics and Outcomes Research
| International | |
|---|---|
| National | |
| Academics | |
